Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer

Table 4 The RP occurrence in NSCLC patients treated with gemcitabine-based induction chemotherapy

Authors	Year	N	IC	Cycles of IC	RT dose (Gy)	CCRT	RP (Grade, %)	Ref
Guilbault C	2017	142	Gemcitabine+ Cisplatin	2	60	Gemcitabine+ Cisplatin	≥3, 10%	10
Kosmidis P	2007	43	Gemcitabine+Paclitaxel	2	63	Paclitaxel	≥2, 22%	21
Schallier D	2009	64	Gemcitabine+Carboplatin+ Paclitaxel	3	66	–	≥3, 12.5%	22
Blanco R	2008	56	Gemcitabine+Cisplatin	3	68.4	Gemcitabine	≥3, 34%	23
Belderbos J	2007	78	Gemcitabine+Cisplatin	2	66	–	≥3, 14%	24
Socinski MA	2008	26	Gemcitabine+Carboplatin	2	74	Gemcitabine	≥3, 37%	25
Arrieta O	2009	19	Gemcitabine+Carboplatin	2	60	Gemcitabine	≥3, 31.6%	26
Kocak M	2009	39	Gemcitabine+Cisplatin	3	66	Docetaxel+cisplatin	NR. 31%	27
Driesen P	2013	49	Gemcitabine+ Cisplatin	3	63	Gemcitabine+ Cisplatin	≥3, 6.5%	28

IC Induction chemotheraoy, RT Radiotherapy, CCRT Concurrent chemoratiotherapy, RP Radiation pneumonitis, NR Not reffered, Ref Reference

ISSN: 1748-717X